Jan 10 (Reuters) - Royalty Pharma RPRX.O said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages its operations as the healthcare firm seeks to simplify corporate structure.

Royalty Pharma buys royalties of future drugs from academic labs and biotechnology companies, which in turn use the cash to fund their research.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))